AI Proteins Announces the Appointment of Dr. Robert Stein to its Scientific Advisory Board

2023-10-04

高管变更疫苗

Dr. Stein is an industry leader with over 35 years of experience in drug development BOSTON--(BUSINESS WIRE)-- AI Proteins, Inc., a growing biotechnology company that utilizes computational de novo protein design to create novel therapeutic miniproteins, today announced the appointment of Robert Stein, MD, PhD, to its Scientific Advisory Board. “The team and I at AI Proteins are ecstatic to welcome Dr. Robert Stein to our Scientific Advisory Board,” said Dr. Chris Bahl, founder, President, and Chief Scientific Officer of AI Proteins. “Bob is an icon in the pharmaceutical industry and a veteran drug hunter with a proven track record of success. He shares our vision for the promise of miniproteins as a next-generation modality with massive therapeutic opportunity. The incredible speed, efficiency, and capacity of our miniprotein platform have yielded a deep pipeline of assets that are poised to begin development. We are grateful to have the opportunity to work closely with Bob, and all of our SAB members, as we navigate this exciting and pivotal moment for AI Proteins.” Dr. Robert Stein, an accomplished medical professional, has held various executive positions in research and development, contributing to the advancement and registration of several pharmaceuticals. Notably, he played a key role in the discovery and development of Sustiva®, Promacta®, and the blockbuster drug Eliquis®. With his expertise in molecular biology, biochemistry, and clinical development, Dr. Stein spearheaded the development of four checkpoint modulatory antibodies and a personalized neo-epitope-directed cancer vaccine. Dr. Stein currently is a Venture Partner at Samsara Biocapital. Additionally, he has held various leadership positions, including President of Roche Palo Alto LLC, Chief Executive Officer of Kinemed, and President of R&D at the immuno-oncology company Agenus. Dr. Stein holds an MD and a PhD in Physiology & Pharmacology from Duke University. "AI Proteins’ compelling de novo protein design platform creates protein-based medicines that can effectively target multiple indications across a wide array of disease areas,” said Robert Stein, MD, PhD. “The rapidly evolving science of miniproteins has the potential to be substantially differentiated from current therapeutic modalities and help deliver better patient outcomes in indications with large unmet need. I look forward to supporting further advancement of this cutting-edge science and ideal therapeutic modality with AI Protein’s seasoned management and expert advisors who have strong protein engineering and drug development experience.” “We are honored to have Dr. Stein join us at this important time for our Company,” said Noah D. Beerman, Chief Executive Officer of AI Proteins. “His appointment strengthens the already deep expertise present in our Scientific Advisory Board. Dr. Stein’s knowledge of drug development and commercialization will have an invaluable impact as AI Proteins enters our next phase of growth. We are excited to have an advisor of Dr. Stein’s caliber join our team and look forward to his insightful scientific and strategic guidance as we bring miniprotein therapeutics into development for indications with serious unmet medical need.” In addition to Dr. Robert Stein, AI Protein’s current SAB members include Dr. Alice Bexon, Dr. Charlotte Deane, Dr. Todd Fehniger, Dr. Justin Gainor, Dr. Dennis Klinman, Dr. Carl Novina, Dr. Eric Rowinsky, and Dr. Omer Yilmaz. About AI Proteins Boston-based AI Proteins is a biotech company on a mission to re-imagine protein therapeutics with a novel approach for designing entirely new proteins. Using AI-based design and a high-throughput drug discovery platform, AI Proteins creates de novo proteins optimized for specific therapeutic applications. The AI Proteins platform enables the development of inexpensive, durable, highly specific proteins that have the potential for oral delivery. Additionally, the AI Proteins platform can dramatically accelerate the development of lead therapeutic candidates ready for IND-enabling studies. For more information, please visit aiproteins.com. View source version on businesswire.com: Contacts Investor Contact: Janhavi Mohite Stern Investor Relations, Inc. janhavi.mohite@sternir.com +1 (212) 362-1200 Source: AI Proteins, Inc. View this news release online at: